[go: up one dir, main page]

WO2005090387A3 - Derives de peptide d'histone h2a et analogues, et methodes d'utilisation - Google Patents

Derives de peptide d'histone h2a et analogues, et methodes d'utilisation Download PDF

Info

Publication number
WO2005090387A3
WO2005090387A3 PCT/IL2005/000328 IL2005000328W WO2005090387A3 WO 2005090387 A3 WO2005090387 A3 WO 2005090387A3 IL 2005000328 W IL2005000328 W IL 2005000328W WO 2005090387 A3 WO2005090387 A3 WO 2005090387A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
protecting against
methods
histone
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2005/000328
Other languages
English (en)
Other versions
WO2005090387A2 (fr
Inventor
Uri Wormser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of WO2005090387A2 publication Critical patent/WO2005090387A2/fr
Publication of WO2005090387A3 publication Critical patent/WO2005090387A3/fr
Anticipated expiration legal-status Critical
Priority to US11/527,162 priority Critical patent/US7528227B2/en
Priority to US11/750,408 priority patent/US7605132B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des peptides dérivés d'un segment d'histone H2A humain correspondant à des résidus d'acides aminé 36-44 d'histone H2A humain qui, lorsqu'ils sont administrés à des animaux, sont capables de réduire ou d'atténuer la gravité de lésions induites par de stimuli nocifs. Sont également décrites des compositions pharmaceutiques et des méthodes d'utilisation de ces peptides. Ces compositions pharmaceutiques conviennent pour le traitement et la prévention de maladies inflammatoires et de maladies auto-immunes, pour le traitement et la prévention de dégâts tissulaires, pour l'inhibition de l'activité de la métalloprotéinase ainsi que pour le traitement et la prévention de maladies associées à la dégradation de la matrice extracellulaire ou des tissus conjonctifs.
PCT/IL2005/000328 2001-08-29 2005-03-23 Derives de peptide d'histone h2a et analogues, et methodes d'utilisation Ceased WO2005090387A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/527,162 US7528227B2 (en) 2004-03-23 2006-09-25 Histone H2A peptide derivatives and uses thereof
US11/750,408 US7605132B2 (en) 2001-08-29 2007-05-18 Protective factors against inflammation, burns and noxious stimuli

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55533404P 2004-03-23 2004-03-23
US60/555,334 2004-03-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/527,162 Continuation-In-Part US7528227B2 (en) 2001-08-29 2006-09-25 Histone H2A peptide derivatives and uses thereof

Publications (2)

Publication Number Publication Date
WO2005090387A2 WO2005090387A2 (fr) 2005-09-29
WO2005090387A3 true WO2005090387A3 (fr) 2006-02-02

Family

ID=34964143

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/000328 Ceased WO2005090387A2 (fr) 2001-08-29 2005-03-23 Derives de peptide d'histone h2a et analogues, et methodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2005090387A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006101187A1 (fr) * 2005-03-22 2006-09-28 Rohto Pharmaceutical Co., Ltd. Peptide qui augmente la production de collagene ou d’acide hyaluronique
WO2008010218A1 (fr) * 2006-07-17 2008-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peptides dérivés de l'histone h2a humaine et leurs procédés d'utilisation
EP2558110B1 (fr) 2010-04-11 2015-06-03 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Extrait et peptides dérivés du groupe oryza sativa japonica et leurs utilisations
EP2611459B1 (fr) 2010-08-31 2019-12-11 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Polypeptides dérivés d'alpha-1 antitrypsin pour l'utilisation dans le traitement de l'inflammation
US9518107B2 (en) 2010-08-31 2016-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof
EP3253774B1 (fr) * 2015-02-08 2018-11-21 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Peptides pour le traitement de maladies prolifératives malignes
CN106397575A (zh) * 2016-10-20 2017-02-15 上海懿贝瑞生物医药科技有限公司 一种具有胞外组蛋白毒性抑制作用的多肽制备方法及用途
CN112745379A (zh) * 2021-01-22 2021-05-04 浙江辉肽生命健康科技有限公司 具有氨基酸结构rdnkktriipr的生物活性肽及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489577A1 (fr) * 1990-12-03 1992-06-10 Celltech Limited Dérivés peptidyliques
WO1998009985A2 (fr) * 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Peptides anti-inflammatoires et leurs utilisations
WO2003017920A2 (fr) * 2001-08-29 2003-03-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Facteurs de protection contre des inflammations, des brulures et des stimuli nocifs
EP1297753A1 (fr) * 2001-10-01 2003-04-02 Societe Des Produits Nestle S.A. Peptides pour l'utilisation comme flavour

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489577A1 (fr) * 1990-12-03 1992-06-10 Celltech Limited Dérivés peptidyliques
WO1998009985A2 (fr) * 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Peptides anti-inflammatoires et leurs utilisations
WO2003017920A2 (fr) * 2001-08-29 2003-03-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Facteurs de protection contre des inflammations, des brulures et des stimuli nocifs
EP1297753A1 (fr) * 2001-10-01 2003-04-02 Societe Des Produits Nestle S.A. Peptides pour l'utilisation comme flavour

Also Published As

Publication number Publication date
WO2005090387A2 (fr) 2005-09-29

Similar Documents

Publication Publication Date Title
RU2007131504A (ru) Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r)
EA200501000A3 (ru) Связывающие агенты, ингибирующие миостатин
TR199800258T1 (xx) Yeni opioid peptidler.
UA100222C2 (uk) Тканинозахисні пептиди і їх застосування
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
WO2010005580A3 (fr) Procédés et compositions de modulateurs à petites molécules de l’activité du facteur de croissance des hépatocytes (facteur de diffusion)
WO2005090387A3 (fr) Derives de peptide d'histone h2a et analogues, et methodes d'utilisation
WO2004100893A3 (fr) Methodes de traitement d'affections inflammatoires a l'aide de ct-3 ou de ses analogues
KR20170138547A (ko) 자가 면역 및 염증성 질환의 치료 및/또는 예방을 위한 짧은 합성 펩타이드
AR044209A1 (es) Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel
WO2004009625A3 (fr) Peptides et derives de peptides destines au traitement des maladies liees a ?-synucleine
WO2007145589A8 (fr) Peptides capables de se lier à un peptide bêta-amyloïde
WO2009106715A3 (fr) Peptide derive d'une proteine de la famille des aquaporines
WO2010112710A3 (fr) Peptides anti-age activateurs du proteasome et compositions les contenant
CA2940751C (fr) Utilisations d'un peptide d'angiotensine (1-7) pour le traitement retarde d'un accident vasculaire cerebral
WO2010086867A3 (fr) Peptides, compositions pharmaceutiques en contenant et leurs utilisations
RU2537560C2 (ru) Тетрапептид и средство, обладающее церебропротекторной и антиамнестической активностями (варианты)
WO2007139433A8 (fr) Substance peptidique normalisant le métabolisme dans les tissus osseux et cartilagineux, composition pharmaceutique à base de ladite substance et procédé d'application afférent
EP1695969A4 (fr) Derives d'acides alpha-amino et leur utilisation comme medicaments
WO2007014253A3 (fr) Methode permettant de traiter ou de prevenir la deterioration, les lesions ou les dommages tissulaires causes par l'insuffisance cardiaque congestive
EP2308837A3 (fr) Dérivés d'acide hydroxamique substitués d'arylsulfonamido en tant qu'inhibiteurs de métalloprotéinases de matrice
WO2003017920A3 (fr) Facteurs de protection contre des inflammations, des brulures et des stimuli nocifs
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
US11879020B2 (en) Cyclic peptidomimetic for the treatment of neurological disorders
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11527162

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 11527162

Country of ref document: US

122 Ep: pct application non-entry in european phase